Anthrax Aktien - 500 Beiträge pro Seite

[GSG9]

VERSAR Expands Anthrax Testing Services Announces Nationwide Emergency Response Service
WEDNESDAY, OCTOBER 24, 2001 9:15 AM
- PRNewswire

VERSAR Expands Anthrax Testing Services Announces Nationwide Emergency Response Service

SPRINGFIELD, Va., Oct 24, 2001 /PRNewswire via COMTEX/ -- VERSAR, INC. announced today that the Company has put into place a nationwide emergency response service for biological, chemical and industrial incidents in the workplace throughout the United States, Canada and Europe. Operating out of regional command centers, VERSAR will respond to actual and threatened terrorist incidents including securing the affected area, sampling and analysis. For a monthly fee customers will receive 24 hour, 7 days a week access to VERSAR`S network of on-site coordinators through a 800 number, secure website, limited telephone and face to face consultation, plus discounts on biological and chemical laboratory fees. VERSAR provides consulting services in mitigating risk to protect employees and ensuring business continuity.

In addition, VERSAR offers comprehensive counter terrorism services including vulnerability assessment, facilities operations, personal protection programs and engineering services. The Company`s emergency response services were recently featured in the Wall Street Journal. To date, VERSAR has conducted more than a dozen anthrax-testing programs for financial institutions and news outlets including CNN and ABC. Testing has used protocols developed by the U.S. Army.

Dr. Ted Prociv, President and CEO of VERSAR said, "As the former head of the Department of Defense chemical and biological program, I know there is a need for immediate site response to potential terrorist situations around the world. With our 15 years of experience in chemical and biological weapons and clean-up, VERSAR is in a unique position to assist business and local government deal with actual or perceived threats."

VERSAR, INC., headquartered in Springfield, VA, is a publicly held professional services firm supporting government and industry in homeland defense and counter-terrorism, environmental health and safety and infrastructure revitalization. VERSAR operates a number of websites, including the corporate web sites, , and a B2B portal for homeland defense and counter-terrorism products and services, a permit support site for auxiliary power generators, and a website for B2B support for architectural and engineering projects using a virtual workspace, at .

This press release contains forward-looking information. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be significantly impacted by certain risks and uncertainties described herein and in Versar`s Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended June 30, 2001.

SOURCE VERSAR, INC.

Leider in DE keine Umsätze, US Konto erforderlich !

Gruß
GSG9

[rescue]

Vergesst endlich Anthrax, das ist in ein paar Wochen durch aber was kommt dann? Viele dieser Dinge können und wollen wir uns jetzt nicht vorstellen aber die Anfangssymtome sind oft sehr ähnlich. Nur schnellste Diagnose kann im kommenden und allen zukünftigen Wintern helfen!
Man muss unbedingt unterscheiden ob es sich um Grippe oder bioterror handelt. Die Grippeepedemie ist für heuer besonders hart prognostiziert ind das weiß auch die US Regierung!

www.fluwatch.com
www.Zymetx.com

BW)(OK-ZYMETX)(ZMTX) ZymeTx Launches Flu Season Surveillance Amid Bioterrorism Fears; NFSN Viewed as Potential Tool in National Counter Bioterrorism

Business Editors/Health & Medical Writers

OKLAHOMA CITY--(BW HealthWire)--Oct. 11, 2001--The National Flu Surveillance Network(TM) (NFSN) today officially launched its 2001-2002 winter flu season surveillance initiative amid high national interest and concern about the prospects of bioterrorism this winter.
"Never before has there been a flu season where obtaining a timely flu diagnosis takes on such importance," commented Norman Proulx, ZymeTx, Inc., president and chief executive officer. "A point-of-care flu diagnostic test adds much-needed certainty to a diagnosis and enables physicians to prescribe appropriate treatment in a prompt manner."
ZymeTx developed the world`s first point-of-care flu diagnostic test using its patented neuraminidase technology, ZstatFlu(R), which delivers 99 percent specificity on positive tests within 20 minutes.
The NFSN, a service of ZymeTx, Inc. (OTCBB:ZMTX), identifies, tracks, monitors and reports the presence and prevalence of flu outbreaks via its Internet site at www.FluWatch.com. Currently 6,300 physicians report influenza test results regularly from more than 1,000 locations across the nation. Physicians use the ZstatFlu diagnostic test to pinpoint flu in their area.
"Anthrax and other biological threats cited as possible weapons initially present as flu-like symptoms," said Dr. Robert Hudson, NFSN Managing Director. "Rapid influenza testing and an extensive surveillance network are critical components in plans to identify potential bioterrorist attacks."
"As the Federal Government engages in preparing a comprehensive Homeland Security plan, it is important to carefully examine the potential of privately developed systems such as the National Flu Surveillance Network to provide intelligence in the country`s efforts to thwart a bio-agent outbreak," stated Oklahoma Governor Frank Keating.
The NFSN posted on its www.FluWatch.com website information about symptoms and characteristics of biological agents that are potential weapons of terrorists.
Currently, public health officials, legislators and primary care providers are debating the nation`s readiness and capabilities in the event of a biological terrorist attack. Jonathan Tucker, Ph.D., of the Monterey Institute of International Studies in Washington, D.C., testified during a U.S. Senate Appropriations hearing that a gap exists in detecting the presence of biological agents and that effective disease surveillance needs to be connected to public health systems. Hudson said he believes ZymeTx`s NFSN is a significant step toward filling the gap Dr. Tucker spoke to in his remarks.
"A number of health and bioterrorism experts across the country brought forth the need for a much broader and more timely disease detection and surveillance as part of a national bioterrorism defense plan over the past few days," said Dr. Robert L. Petrone, Bioterrorism Preparedness and Response Coordinator for the Oklahoma State Department of Health. "The National Flu Surveillance Network represents a useful model of surveillance technology and data presentation that can assist our country in successfully combating bioterrorism."
"The National Flu Surveillance Network at www.FluWatch.com already reports in virtual real time the detection and location of influenza across the United States," said Hudson. "Our established network and reporting system has the potential to be a model for national counter-bioterrorism surveillance."
Hudson said the NFSN could alert public health and investigative authorities of variations in normal influenza patterns. This is especially important when an influx of patients with flu-like symptoms are tested and found not to have the flu, thus triggering protocols to quickly identify the causative agent.
The NFSN is the only influenza surveillance network that operates year round. "Our surveillance indicated that 38 states reported positive cases of influenza this summer," said Hudson. "Though primarily a winter disease, influenza is present year round, as is our surveillance and reporting."

About The Company

ZymeTx, Inc., headquartered in Oklahoma City, is a biotechnology company engaged in the development of technology to produce products for the diagnosis and treatment of viral disease, viral management and disease surveillance. The company developed ZstatFlu, the world`s first rapid point-of-care test capable of detecting both Influenza A and B, and the National Flu Surveillance Network(TM) (NFSN), a network of physician sites across the country that use ZstatFlu to track influenza in their communities and practices. Additional information on ZymeTx and NFSN can be obtained by accessing the web sites at www.zymetx.com and www.FluWatch.com.

This press release may contain forward-looking statements, including statements regarding expected future results of operations, which are subject to risks and uncertainties. All forward-looking statements in this press release are based upon historical information available as of the date of this release. Such historic information may change or become invalid after the date of this release, and by making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. The Company`s SEC filings contain additional discussions about those facts, which could cause actual results to differ from management`s expectations.

OKLAHOMA CITY & SAN ANTONIO--(BW HealthWire)--Oct. 19, 2001-- ZymeTx, Inc. (OTCBB: ZMTX):

Contract Provides Specialized Employment Opportunities for
People Who are Blind and Visually Impaired

San Antonio Lighthouse to Assemble, Distribute ZstatFlu
Diagnostic Test Kits

ZymeTx, Inc. (OTCBB:ZMTX) and San Antonio Lighthouse today announced the formation of a new manufacturing and distribution partnership to supply the Company`s patented rapid point-of-care influenza diagnostic test called ZstatFlu to all entities of the United States Federal Government.
The agreement was structured in accordance with the "set aside" provisions of the Javits-Wagner-O`Day Act (JWOD), which allow qualified agencies, such as the San Antonio Lighthouse, to be mandatory sources of designated products for United States Government and military entities. Therefore, the ZstatFlu influenza diagnostic test, produced and distributed through the San Antonio Lighthouse, becomes the exclusive flu test to all federal government customers.
"Our partnership with San Antonio Lighthouse represents an important development in ZymeTx`s initiative to create a market opportunity for our flu diagnostic test with U.S. Government entities, particularly the military and VA hospitals," said Norman Proulx, ZymeTx`s Chief Executive Officer.
"The collaboration with San Antonio Lighthouse, and the placement of ZstatFlu on the Government procurement list, is a prime example of the kind of sustained sales and distribution arrangements we have been focused on securing for over a year," said Proulx. "We are coordinating with San Antonio Lighthouse and with government and military officials to promote comprehensive influenza disease management in different segments of government medical care, including military induction centers and workplace health programs."
"The nation`s fear of a biological agent attack has increased the importance of obtaining a rapid flu diagnosis," said Robert J. Hudson, M.D., Vice President and Medical Director at ZymeTx. "All medical establishments will be looking for a diagnostic to separate the flu patient from the non-flu patient. We see a tremendous opportunity for the application of our test within government medical agencies, veterans hospitals and for use in military operations within war zone settings," he said.
Using its workforce of people who are blind or visually impaired, San Antonio Lighthouse will assemble, package, inspect and distribute ZstatFlu tests for the JWOD contract through it`s affiliation with the National Industries for the Blind (NIB), a nonprofit agency that facilitates the JWOD program under the authority of the Committee for Purchase from Blind and Other Severely Handicapped. San Antonio Lighthouse is now completing validation required for compliance with the Food and Drug Administration`s Good Manufacturing Procedures.
"Since more than half of our funding comes from JWOD contracts, we are careful in selecting partners with products we are confident offer potential to build a sustainable employment for people who are blind. In that regard, we are pleased to add ZymeTx and its ZstatFlu flu test to our preferred vendor list," said Bob R. Plunkett, President of San Antonio Lighthouse.

About the Companies

The San Antonio Lighthouse is a non-profit 501(c)(3) organization incorporated in the State of Texas, operating as a light manufacturing assembly plant and rehabilitation program (William Judson Center). The San Antonio Lighthouse has provided employment opportunities and rehabilitation services to people who are blind or visually impaired in San Antonio and Texas for over 60 years. The San Antonio Lighthouse manages and operates a 58,000 sq. ft. facility in San Antonio with employment of over 300 and total sales in excess of $25 million.

ZymeTx, Inc., headquartered in Oklahoma City, is a biotechnology company engaged in the development of technology to produce products for the diagnosis and treatment of viral disease, viral management and disease surveillance. The company developed ZstatFlu, the world`s first rapid point-of-care test capable of detecting both Influenza A and B, and the National Flu Surveillance Network(TM) (NFSN), a network of physician sites across the country that use ZstatFlu to track influenza in their communities and practices. Additional information on ZymeTx and NFSN can be obtained by accessing the web sites at www.zymetx.com and www.fluwatch.com.

This press release may contain forward-looking statements including statements regarding expected future results of operations, which are subject to risks and uncertainties. All forward-looking statements in this press release are based upon historical information available as of the date of this release. Such historic information may change or become invalid after the date of this release, and by making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. The Company`s SEC filings contain additional discussions about those facts, which could cause actual results to differ from management`s expectations.